Search results for: Innovation Policy Prize
Filter search results
OHE’s Devlin Co-Author on Prize-Winning EQ-5D Paper
14 October 2014
…of EQ-5D, potential influence on policy makers, and originality and innovation. For additional information please contact Nancy Devlin. Open access: Gutacker, N., Bojke, C., Daidone, S., Devlin, N. & Street,…
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
How can fair pricing systems for medicines that balance both access and innovation be designed? This was the question posed by the inaugural OHE Policy Innovation Prize. This Insight looks…
Mata Charokopou – 2022 Prize Finalist
18 January 2023
…Greece, in 2010, with a PharmD in Pharmacy and she received a Master of Science in Health Economics, Policy and Law from the Erasmus University of Rotterdam, Netherlands, in 2011….
James Zackheim – 2022 Prize Finalist
18 January 2023
Dr. James Zackheim, PhD, Vice President – Head of Corporate Strategy and former Head of Patient Access & Pricing in UCB. He is responsible for providing leadership and strategic direction…
Aidan Hollis – 2022 Prize Winner
18 January 2023
…obtained a PhD in economics. He has worked in the private sector and in government. His research focuses on innovation and competition in pharmaceutical markets, and he has published over…
Lancelot Henry de Frahan – 2022 Prize Finalist
18 January 2023
Dr. Lancelot Henry de Frahan, PhD, post–doctoral researcher at the Economics department at the University of Chicago. His research specializes in price theory, labor economics and public finance with a…
Mike Paulden – 2022 Prize Finalist
18 January 2023
Dr Mike Paulden, PhD, is an Associate Professor at the School of Public Health, University of Alberta, Canada. He is a health economist with expertise in the economic evaluation of…
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
…the future of innovation. To aid policymakers in understanding the potential impacts of drug pricing policy on future innovation, the Congressional Budget Office (CBO) has developed a model that simulates…
Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine
1 April 2020
…product profile (TPP), which does not yet exist and would need to be agreed upon. It could be structured as a market entry prize (lump sum) or a price-volume commitment;…